Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allylestrenol is a synthetic progestogen (progestin) structurally related to progesterone, used primarily to prevent premature labor and recurrent or threatened miscarriage in pregnant women. It acts as an agonist of the progesterone receptor, supporting pregnancy by promoting endometrial receptivity for embryo implantation, maintaining the uterine lining, and relaxing uterine smooth muscle. Its mechanism of action is multimodal: it stimulates trophoblastic function (enhancing production of human chorionic gonadotropin and thus endogenous progesterone), exerts placentotropic effects, and has β2-adrenergic activity that relaxes myometrial muscle to inhibit uterine contractions. Allylestrenol is metabolized in the liver (mainly via CYP3A4), with a biological half-life of several hours; its main active metabolite is 17α-allyl-19-nortestosterone[1][2][3][6][8]. The drug has little estrogenic or androgenic activity compared to other 19-nortestosterone derivatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allylestrenol.